Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Plus Radiotherapy for Second-Line ESCC
NCT07188103Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Progression-Free Survival at 36 months and Adverse Events at 36 months. Started Jul 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07188103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188103.